BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7713987)

  • 1. "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
    Cimoli G; Valenti M; Noviello E; Parodi S; Mazzoni A; Rovini E; De Sessa F; Russo P
    J Cancer Res Clin Oncol; 1995; 121(3):155-63. PubMed ID: 7713987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
    Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
    Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks.
    Noviello E; Aluigi MG; Cimoli G; Rovini E; Mazzoni A; Parodi S; De Sessa F; Russo P
    Mutat Res; 1994 Nov; 311(1):21-9. PubMed ID: 7526171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circumvention of atypical multidrug resistance with tumor necrosis factor.
    Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
    Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53.
    Vikhanskaya F; Clerico L; Valenti M; Stanzione MS; Broggini M; Parodi S; Russo P
    Int J Cancer; 1997 Jul; 72(1):155-9. PubMed ID: 9212237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.
    Alaoui Jamali MA; Yin MB; Mazzoni A; Bankusli I; Rustum YM
    Cancer Chemother Pharmacol; 1989; 25(2):77-83. PubMed ID: 2598402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
    Perry WL; Shepard RL; Sampath J; Yaden B; Chin WW; Iversen PW; Jin S; Lesoon A; O'Brien KA; Peek VL; Rolfe M; Shyjan A; Tighe M; Williamson M; Krishnan V; Moore RE; Dantzig AH
    Cancer Res; 2005 Aug; 65(15):6593-600. PubMed ID: 16061639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
    Epstein RJ; Smith PJ
    Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
    Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
    Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
    Harker WG; Slade DL; Drake FH; Parr RL
    Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
    Hazlehurst LA; Valkov N; Wisner L; Storey JA; Boulware D; Sullivan DM; Dalton WS
    Blood; 2001 Sep; 98(6):1897-903. PubMed ID: 11535527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.
    Smith PJ; Morgan SA; Fox ME; Watson JV
    Biochem Pharmacol; 1990 Nov; 40(9):2069-78. PubMed ID: 2173600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
    Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
    Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide-induced DNA damage in human tumor cells: requirement for cellular activating factors.
    Sinha BK; Eliot HM
    Biochim Biophys Acta; 1991 Sep; 1097(2):111-6. PubMed ID: 1655044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells.
    Mazzoni A; Trave F
    Oncol Res; 1993; 5(2):75-82. PubMed ID: 8364256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
    Damle B; Desai P
    Oncol Res; 1994; 6(2):49-57. PubMed ID: 7949465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.